Brookline Capital Management Predicts IceCure Medical Q3 Earnings

Key Points

• Brookline Capital Management forecasts that IceCure Medical will report Q3 2025 earnings of ($0.05) per share, maintaining a "Buy" rating on the stock.
• The company reported a negative net margin of 317.62% and a negative return on equity of 136.96% in its previous quarterly earnings.
• IceCure Medical has a consensus rating of "Moderate Buy" with an average target price of $2.64 from multiple research analysts.

IceCure Medical Ltd. (NASDAQ:ICCM - Free Report) - Research analysts at Brookline Capital Management issued their Q3 2025 earnings estimates for shares of IceCure Medical in a research note issued on Monday, October 6th. Brookline Capital Management analyst K. Dolliver forecasts that the company will post earnings per share of ($0.05) for the quarter. Brookline Capital Management has a "Buy" rating on the stock. The consensus estimate for IceCure Medical's current full-year earnings is ($0.28) per share. Brookline Capital Management also issued estimates for IceCure Medical's Q4 2025 earnings at ($0.04) EPS.

IceCure Medical (NASDAQ:ICCM - Get Free Report) last released its quarterly earnings data on Wednesday, August 13th. The company reported $0.06 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.06) by $0.12. IceCure Medical had a negative net margin of 317.62% and a negative return on equity of 136.96%. The firm had revenue of $0.66 million for the quarter, compared to analysts' expectations of $0.90 million.

ICCM has been the topic of several other research reports. Loop Capital set a $2.77 price target on shares of IceCure Medical in a research report on Wednesday, August 13th. Wall Street Zen cut shares of IceCure Medical from a "hold" rating to a "sell" rating in a research report on Saturday, July 12th. Weiss Ratings reiterated a "sell (e+)" rating on shares of IceCure Medical in a research report on Wednesday. Zacks Research cut shares of IceCure Medical from a "strong-buy" rating to a "hold" rating in a report on Friday, August 15th. Finally, HC Wainwright upped their price objective on shares of IceCure Medical from $2.00 to $2.50 and gave the stock a "buy" rating in a report on Tuesday. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, IceCure Medical has a consensus rating of "Moderate Buy" and an average target price of $2.64.

IceCure Medical Price Performance

Shares of NASDAQ ICCM opened at $0.99 on Thursday. IceCure Medical has a 1 year low of $0.51 and a 1 year high of $1.66. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.18 and a quick ratio of 0.88. The company's 50-day moving average is $0.98 and its 200 day moving average is $1.04. The stock has a market capitalization of $68.09 million, a P/E ratio of -6.20 and a beta of 0.31.

About IceCure Medical

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.